Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - BMO Capital raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $640.00 from $600.00 on Monday, while maintaining an Outperform rating on the stock. The biotech giant, currently trading at $568.37 with a market capitalization of $58.9 billion, shows strong fundamentals with a P/E ratio of 13.7.
The upgrade follows what BMO described as a "much-needed clean quarter" for Regeneron, which the firm believes sets the company on the right path heading into the second half of 2025. According to InvestingPro data, 10 analysts have recently revised their earnings estimates upward for the upcoming period.
BMO noted that Regeneron’s strong second-quarter performance marks progress in the company’s efforts to regain competitive positioning for its Eylea franchise, though clinical and regulatory missteps continue to weigh on shares. With annual revenue of $14.2 billion and a healthy current ratio of 4.6, the company maintains a solid financial foundation. InvestingPro’s Fair Value analysis suggests the stock is currently undervalued.
The firm identified commercial execution as a core focus for Regeneron in the second half of the year, along with clearing regulatory hurdles for key Eylea HD label expansions that could accelerate growth.
BMO also highlighted upcoming clinical milestones, particularly the LAG3 first-line Melanoma data expected in late 2025 or early 2026, as important factors in Regeneron’s ongoing turnaround story.
In other recent news, Regeneron Pharmaceuticals reported impressive financial results for the second quarter of 2025, with earnings per share reaching $12.89, significantly exceeding the forecast of $8.50 by 51.65%. The company’s revenue also outperformed expectations, totaling $3.68 billion compared to the projected $3.29 billion. Bernstein SocGen Group responded to these strong earnings by raising its price target for Regeneron to $753.00, maintaining an Outperform rating despite some regulatory setbacks. The company achieved quarterly revenues of $3.7 billion, surpassing Bernstein’s and consensus expectations by 13% and 11%, respectively.
Leerink Partners also reiterated an Outperform rating for Regeneron, setting a price target of $645.00 based on the company’s promising growth outlook and attractive valuation. Leerink projects a 5-year compound annual growth rate of 7% for revenue and 10% for earnings per share from 2025 to 2030. Additionally, Leerink noted the management’s focus on Lynozyfic’s profile in multiple myeloma and plans for a head-to-head trial against Darzalex in the fourth quarter. These developments highlight Regeneron’s continued strong performance across its major products, including Eylea and Eylea HD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.